These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 10803741

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D, Eriksen J, Maare C, Friche E, Skovsgaard T.
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multidrug resistance-modifying components in human plasma with potential clinical significance.
    Mülder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J.
    J Exp Ther Oncol; 1996 Jan; 1(1):13-22. PubMed ID: 9414384
    [Abstract] [Full Text] [Related]

  • 6. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
    Hatanaka H, Abe Y, Naruke M, Asai S, Miyachi H, Kawakami T, Nagata J, Kamochi J, Kijima H, Yamazaki H, Scanlon KJ, Ueyama Y, Nakamura M.
    Anticancer Res; 2001 Jan; 21(2A):879-85. PubMed ID: 11396179
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
    Moretti JL, Duran Cordobes M, Starzec A, de Beco V, Vergote J, Benazzouz F, Boissier B, Cohen H, Safi N, Piperno-Neumann S, Kouyoumdjian JC.
    J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
    Kim HS, Min YD, Choi CH.
    Biochem Biophys Res Commun; 2001 Apr 27; 283(1):64-71. PubMed ID: 11322768
    [Abstract] [Full Text] [Related]

  • 14. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR.
    Invest New Drugs; 2007 Apr 27; 25(2):115-22. PubMed ID: 17072745
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
    Lehne G, Mørkrid L, den Boer M, Rugstad HE.
    Int J Clin Pharmacol Ther; 2000 Apr 27; 38(4):187-95. PubMed ID: 10783828
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.